آخرت سے متعلق ”ترجمان القرآن“ کے کلامی مباحث کا تجزیاتی مطالعہ

In this universe, if we look at the arrival of a human being, it will open up to us the secret that man did not come in this world suddenly, but he had gone through several worlds before stepping into this universe. The First World is called spiritual world where his soul was present and the argument is that when the soul enters the body of the baby and he starts to move in the womb of the mother, so the question now arises where was that soul before it entered the baby’s body? And where did that soul come from? Where it was and wherever it came from, the name of that universe is Spiritual world. After the spiritual world, there is a second world in the womb of the mother. In this world a man must live for at least nine months. Stop for a minute to see this amazing system of power that a baby remains alive in a moving grave for at least nine months. The object is to say that if a human being has to go through two worlds before coming into the universe, so if a fourth world is accepted after this world, what is the rational prohibition behind it? The life in the fourth world is called the life of Hereafter. If there is any disagreement with this name then let’s another name, but a fourth world still have to believe, because when the soul comes out of body after death, the same question will arise here that where did the soul go? In this article, it is examined that how author of “Tarjuman al-Qur’an” Abul Kalam Azad has proved the reality of life of Hereafter and what kind of arguments have given as an evidence in this tafsir?

The Association Between Asymptomatic and Mild Neurocognitive Impairment and Adherence to Antiretroviral Therapy Amongst People Living With Hiv

Background: HIV disease is associated with neurocognitive impairment which is one of the neurological complications of the viral infection. The spectrum of HIV Associated neurocognitive impairment has significantly changed since the advent of ART. The inclusion of the asymptomatic but cognitively impaired population of patients has changed the dynamics of this population, and requires further research to identify the impact it has on the progression of the disease as well as on any other aspects. Poor adherence to ART is one of the main causes of treatment failure and studies done previously point towards the milder forms of Neurocognitive Impairment as being a cause of poor adherence, among other aspects. Primary Objective: To assess the association between the milder forms of neurocognitive impairment and adherence to ART. Methods: The study was a cross-sectional survey, with consecutive sampling, with a total sample size of 218 patients. An association was sought between cognitive status and adherence as measured by objective means, self-reported means and last viral load value as a surrogate marker. The study utilised quantitative primary data on pre-defined baseline characteristics, neurocognitive assessment by MOCA, instrumental activities of daily living by Lawton score and objective and subjective adherence measures by medication possession ratio (MPR) and simplified medication adherence questionnaire (SMAQ) respectively. Univariate and bivariate analysis was conducted to determine the strengths of association between various predictor and the outcome variables. Results: A final sample size of 218 was selected out of all those eligible (500 patients). All study participants underwent a neurocognitive assessment, which revealed 69% minor neurocognitive impairment while 31% had no neurocognitive impairment. No patient was identified with HIV associated dementia on screening. Secondly, all study participants underwent adherence assessment which revealed optimal adherent rates of 66% and 77% by objective (by MPR) and subjective (SMAQ) measures respectively. There were no statistically significant differences in the baseline characteristics (age, gender, education, marital status, living arrangements, employment status, level of income) between the group of participants with cognitive impairment and those without impairment (p-value > 0.05). Similarly, when the same group were compared on characteristics related to their HIV diagnosis and treatment, no statistically significant differences were observed (p-value > 0.05). Discussion: Even though the rate of cognitive impairment in this study was high, it corresponds to some of the studies earlier carried out (CHARTER study = 53%), the majority of which were asymptomatic and Mild Cognitive Disorders, while only